Assessment of cardiovascular risk from the use of an interleukin-1 inhibitor in patients with severe tophaceous gout

Assessment of cardiovascular risk from the use of an interleukin-1 inhibitor in patients with severe tophaceous gout

It is suggested that interleukin (IL)-1β inhibition may promote a reduction in the risk of cardiovascular diseases; however, the mechanism of this impact has not been adequately investigated.Objective: to evaluate the impact of canakinumab therapy on the structural and functional properties of the v...

Full description

Saved in:
Bibliographic Details
Main Authors: M. S. Eliseev, O. V. Zhelyabina, E. I. Markelova, D. S. Novikova, S. A. Vladimirov, Yu. O. Korsakova, E. N. Aleksandrova, A. A. Novikov, E. L. Nasonov
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2016-03-01
Series:Современная ревматология
Subjects:
gout
interleukin-1 inhibitor canakinumab
cardiovascular diseases
atherosclerosis
arterial stiffness
Online Access:https://mrj.ima-press.net/mrj/article/view/664
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://mrj.ima-press.net/mrj/article/view/664

Similar Items